Ohio Pediatric Research Association

Dayton, Ohio 45414

1 studies enrolling now · 29 studies all time

What they study most

Atopic Dermatitis, Atopic Dermatitis (AD), Attention Deficit Hyperactivity Disorder (ADHD), Child Development, Functional Constipation in Children Ages 6-17 Years, Growth, Growth and Tolerance, Healthy Infants, Healthy, Full-term Infants Who Are Formula-fed, Influenza, Irritable Bowel Syndrome With Constipation, Meningitis, Meningococcal

Studies at this site

• A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts — Recruiting now
• A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants — Running, not enrolling
• The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. — Stopped early
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• BIG Study (Brain, Immune, and Gut Health Evaluation of Infants/Young Children Fed Infant Formula, and Later Supplemental Toddler Nutrition, With 5 Specific HMOs) — Completed
• Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis — Completed
• A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3) — Completed
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) — Completed
• TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis — Completed
• Study of Ruxolitinib Cream in Children With Atopic Dermatitis — Completed
• Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) — Stopped early
• Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years — Completed
• Infant Formula and Toddler Drink Feeding Intervention — Stopped early
• Growth and Tolerance of Young Infants Fed Infant Formula — Completed
• A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation — Stopped early
• A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis — Completed
• Growth and Tolerance of Infants Fed Formula for 16 Weeks — Completed
• Impact of Infant Formula on Caregiver-perceived Intolerance — Completed
• Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms — Completed
• Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose — Completed
• A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC) — Completed
• Acceptance Of A Partially-Hydrolyzed Infant Formula — Completed
• A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age — Completed
• Gastrointestinal Tolerance Evaluation of an Infant Formula — Completed
• Growth and Tolerance of Healthy Term Infants Fed Cow's Milk-Based Infant Formulas — Withdrawn before enrolling
• Growth and Tolerance of Cow's Milk-Based Infant Formulas — Completed
• A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years — Completed
• A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years — Completed